Study guide
9.2 Endocrine Emergencies
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
9.2 Endocrine Emergencies
Key Takeaways Explain This Topic AI
In DKA and HHS management, intravenous fluids are the most critical initial intervention, followed by insulin therapy; however, insulin must be delayed if the serum potassium is < 3.5 mEq/L (2024 adult consensus).
The Burch-Wartofsky Point Scale is a validated tool to help differentiate impending or actual thyroid storm from uncomplicated thyrotoxicosis based on clinical criteria.
In thyroid storm, propylthiouracil (PTU) is often preferred over methimazole for acute management because PTU both blocks new thyroid hormone synthesis and inhibits peripheral conversion of T4 to T3.
In myxedema coma, empiric intravenous glucocorticoids (e.g., hydrocortisone) must be administered before or simultaneously with intravenous levothyroxine to prevent precipitating acute adrenal crisis.
Acute adrenal crisis typically presents with refractory vasodilatory shock and requires immediate administration of intravenous hydrocortisone (typically 100 mg followed by stress-dose infusions or intermittent boluses).
Last updated: October 2026
Endocrine Emergencies in the ICU
Endocrine emergencies can present as profound metabolic derangements and shock. Prompt recognition and protocolized treatment are essential for reducing morbidity and mortality.
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS)
Both DKA and HHS are life-threatening complications of diabetes mellitus, characterized by absolute or relative insulin deficiency and an excess of counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone).
Pathophysiology and Diagnosis
DKA: Typically occurs in Type 1 diabetes. Absolute insulin deficiency leads to uninhibited lipolysis, generating free fatty acids that the liver converts into ketone bodies (beta-hydroxybutyrate and acetoacetate). This results in an elevated anion gap metabolic acidosis.
Diagnostic Criteria (2024 adult consensus): Glucose ≥ 200 mg/dL or a known history of diabetes, whatever the glucose (about 10% present with euglycemic DKA, < 200 mg/dL), plus elevated ketones (β-hydroxybutyrate ≥ 3.0 mmol/L) and pH < 7.30 and/or bicarbonate < 18 mEq/L.
HHS: Typically occurs in Type 2 diabetes. The presence of a small amount of endogenous insulin prevents significant ketogenesis, but severe hyperglycemia leads to profound osmotic diuresis and severe dehydration.
Diagnostic Criteria: Glucose > 600 mg/dL, arterial pH > 7.30, serum bicarbonate > 18 mEq/L, serum osmolality > 320 mOsm/kg, and absent/minimal ketones.
Management Steps
Intravenous Fluids: The first and most critical step. Patients have significant fluid deficits (often 3-6 liters in DKA and up to 8-10 liters in HHS). Start with isotonic saline (0.9% NaCl) or a balanced crystalloid at 500-1,000 mL/hr for the first 2-4 hours (smaller 250 mL boluses in older adults, heart failure, or dialysis). Once hemodynamically stable, switch to 0.45% NaCl if corrected serum sodium is normal or high.
Potassium Replacement: Patients have a profound total body potassium deficit, even if the initial serum potassium is high (due to extracellular shift from acidosis and insulin deficiency).
If K+ is < 3.5 mEq/L: Hold insulin , give IV potassium (about 10 mEq/hr) until K+ > 3.5 mEq/L.
If K+ is 3.5 - 5.0 mEq/L: Add 20-30 mEq K+ to each liter of IV fluid to keep K+ between 4-5 mEq/L.
If K+ is > 5.0 mEq/L: Do not give K+ until it falls below 5.0; recheck 2 hours after insulin starts, then every 4 hours.
Insulin Therapy: Start an IV regular insulin infusion at 0.1 Units/kg/hr. Ensure K+ is > 3.5 mEq/L before starting. When blood glucose falls below 250 mg/dL (DKA) or 300 mg/dL (HHS), add 5-10% dextrose to the IV fluids and decrease the insulin rate (about 0.05 Units/kg/hr) to keep glucose near 200 mg/dL until resolution.
Bicarbonate: The routine use of sodium bicarbonate in DKA is not recommended. It may be considered only for severe acidemia (pH < 7.0) due to the risk of paradoxical intracellular acidosis, hypokalemia, and delayed clearance of ketones.
- Thyroid Emergencies
- Thyroid Storm
Thyroid storm is a rare, extreme manifestation of thyrotoxicosis with a high mortality rate. It is often precipitated by an acute event (infection, surgery, trauma, iodine load) in a patient with underlying hyperthyroidism.
Diagnosis: The Burch-Wartofsky Point Scale (BWPS) uses clinical criteria (temperature, CNS effects, GI/hepatic dysfunction, heart rate, and heart failure) to assess the likelihood of thyroid storm. A score of 45 or greater is highly suggestive of thyroid storm.
Management (The "5 B's" Concept):
Block synthesis (Thioamides): Propylthiouracil (PTU) or methimazole. PTU is generally preferred in storm because it blocks both new hormone synthesis and peripheral conversion of T4 to active T3.
Block release (Iodine): SSKI or Lugol's solution. Must be given at least 1 hour after thioamides to prevent the iodine from being used to synthesize new thyroid hormone.
Block T4 to T3 conversion (Corticosteroids): High-dose hydrocortisone or dexamethasone prevents peripheral conversion and treats potential relative adrenal insufficiency.
Beta-blockade: Propranolol is preferred as it controls adrenergic symptoms and also inhibits peripheral T4 to T3 conversion at high doses. Esmolol is an alternative for tighter heart rate control.
Banish the trigger/supportive care: Treat the underlying infection, aggressive cooling, and fluid resuscitation.
Myxedema Coma
Myxedema coma is the extreme manifestation of severe hypothyroidism, characterized by altered mental status, profound hypothermia, bradycardia, hypotension, and hypoventilation (leading to hypercapnia).
Management:
Thyroid Hormone Replacement: Intravenous levothyroxine (T4). IV liothyronine (T3) may also be used for faster onset but carries a higher risk of arrhythmias.
Corticosteroids: Critical step. Empiric IV hydrocortisone (stress dose) must be given before or alongside thyroid hormone. Patients with myxedema coma may have coexisting adrenal insufficiency (Schmidt syndrome) or decreased adrenal reserve; restoring metabolic rate with thyroid hormone without steroids can precipitate acute adrenal crisis.
Supportive Care: Passive rewarming (active rewarming can cause vasodilation and worsening shock), mechanical ventilation, and IV fluids.
Adrenal Insufficiency and Acute Adrenal Crisis
Acute adrenal crisis is a life-threatening state of severe cortisol deficiency, commonly presenting as refractory distributive (vasodilatory) shock, hypoglycemia, hyponatremia, and hyperkalemia (if primary insufficiency involves aldosterone deficiency).
Primary vs. Secondary:
Primary (Addison's disease): Adrenal gland destruction. Leads to deficiency of both cortisol and aldosterone (mineralocorticoid). Characterized by hyperpigmentation, hyponatremia, and hyperkalemia.
Secondary/Tertiary: Pituitary or hypothalamic dysfunction (often due to abrupt cessation of chronic exogenous steroids). Leads to cortisol deficiency, but aldosterone remains intact (regulated by the RAAS system). Potassium is usually normal.
Management:
Glucocorticoids: Intravenous hydrocortisone (typically 100 mg IV bolus followed by 50 mg IV every 6 hours, or a continuous infusion). Hydrocortisone has both glucocorticoid and mineralocorticoid activity at high doses.
Fluids: Aggressive resuscitation with normal saline or D5NS to correct volume depletion and hypoglycemia.
Mineralocorticoids: Fludrocortisone is generally not needed acutely if stress doses of hydrocortisone are given (> 50 mg/day of hydrocortisone provides sufficient mineralocorticoid activity), but may be required for long-term maintenance in primary adrenal insufficiency once hydrocortisone doses are tapered.